This trial will test how well a weekly insulin injection and a small sensor inserted under the skin can control blood sugar in people with type 2 diabetes. Participants will have to wear the sensor and inject insulin for 8 months.
- Type 2 Diabetes
1 Primary · 0 Secondary · Reporting Duration: From initiation week 0 (Visit 3) to week 26 (Visit 26)
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
50 Total Participants · 1 Treatment Group
Primary Treatment: Insulin Icodec · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|Novo Nordisk Investigational Site||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
How many prior treatments have patients received?
Frequently Asked Questions
Has the FDA endorsed Insulin Icodec?
"There is a history of clinical data that supports the safety profile of Insulin Icodec, which has earned it a score of 3." - Anonymous Online Contributor
Which areas are offering access to this research protocol?
"Currently, nine different sites are running this trial. Choosing a centre close to you is encouraged as it helps reduce the need for travel; these locations include Sacramento, Minneapolis and Las Vegas in addition to six other cities." - Anonymous Online Contributor
Are there still openings in this research study for participants?
"As indicated on clinicaltrials.gov, the posting for this study is no longer accepting patients. It was initially published on April 11th 2023 and most recently edited on April 9th 2023. However, there are numerous other trials that require participants; at current count 1423 studies have open recruitment." - Anonymous Online Contributor